Your browser doesn't support javascript.
loading
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.
Pemmaraju, Naveen; Wilson, Nathaniel R; Senapati, Jayastu; Economides, Minas P; Guzman, Monica L; Neelapu, Sattva S; Kazemimood, Rossana; Davis, Richard Eric; Jain, Nitin; Khoury, Joseph D; Sugita, Mayumi; Cai, Tianyu; Smith, Julianne; Frattini, Mark G; Garton, Andrew; Roboz, Gail; Konopleva, Marina.
Afiliación
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: npemmaraju@mdanderson.org.
  • Wilson NR; Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX, United States.
  • Senapati J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Economides MP; Department of Hematology and Oncology, New York University, NY, United States.
  • Guzman ML; Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY, United States.
  • Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Kazemimood R; Department of Pathology, University of Rochester Medical Center, Rochester, NY, United States.
  • Davis RE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Khoury JD; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Sugita M; Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY, United States.
  • Cai T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Smith J; Cellectis, S.A., Paris, France.
  • Frattini MG; Cellectis, Inc., New York, NY, United States.
  • Garton A; Cellectis, Inc., New York, NY, United States.
  • Roboz G; Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY, United States.
  • Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Leuk Res ; 121: 106928, 2022 10.
Article en En | MEDLINE | ID: mdl-35963025
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles / 9_ODS3_accidentes_transito Problema de salud: 2_accidentes_transito / 6_skin_diseases / 9_abuso_substancias Asunto principal: Neoplasias Cutáneas / Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas / Receptores Quiméricos de Antígenos / Trastornos Mieloproliferativos Límite: Humans Idioma: En Revista: Leuk Res Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles / 9_ODS3_accidentes_transito Problema de salud: 2_accidentes_transito / 6_skin_diseases / 9_abuso_substancias Asunto principal: Neoplasias Cutáneas / Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas / Receptores Quiméricos de Antígenos / Trastornos Mieloproliferativos Límite: Humans Idioma: En Revista: Leuk Res Año: 2022 Tipo del documento: Article